Next, the smuLymphNet framework was applied to 1,143 WSIs of H&E‐stained LN sections from 154 breast cancer patients, encompassing (1) 2,096 LNs from 99 TNBC patients, (2) 991 LNs from 43 human epidermal growth factor receptor 2 (HER2)‐positive/oestrogen receptor (ER)‐negative patients, and (3) 214 LNs from 12 ER‐positive patients (see CONSORT diagram in Figure 1). Here, ERBB2 is linked to breast carcinoma.